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Background: The identiﬁcation of prostate cancer (PC) is important in men aged  65 years. We
examined complete transurethral resection of prostate (TURP) specimens to quantify the incidence and
nature of PC in men aged  65 years.
Methods: A prospective multi-institutional database included TURP specimens. The cohort was strati-
ﬁed into two groups according to age. For men aged  65 years, the entire specimen was submitted for
histological analysis, while the TURP specimens from men aged > 65 years were sampled following
standard guidelines.
Results: A total of 923 men were included, with 224 in the younger group. PC was identiﬁed in 13.4% in
men aged  65 years, compared with 28.7% the older group. The younger group had a lower proportion
of Gleason score  7 (30% compared with 40%) and higher rates of pT1a (57% compared with 43%). In
men aged  65 years with cancer, tumor was identiﬁed in one block in 15 of 30 cases (50%). Following
diagnosis, 4/30 underwent radical prostatectomy, 5/30 underwent curative radiotherapy, 10/30 androgen
deprivation, and 1/30 received palliative radiotherapy.
Conclusion: Incidental PC in men aged  65 years is not uncommon. Our results suggest that TURP
specimens in men aged  65 years should be completely assessed. Underidentiﬁcation of cancer may
occur as a result of increasing use of laser prostatectomy and the consequent loss of tissue for patho-
logical examination.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is common, presenting clinically in 8% of men.
On autopsy, up to 60% of 70-year-olds and 80% of 80-year-olds are
found to have latent prostate cancer.1 The landmark study by Bill-
Axelson et al2 in 2011, conﬁrmed early prostatectomy was signiﬁ-
cantly associated with reduced mortality when compared with
watchful waiting. At 23-year follow up, men aged  65 years
experienced the greatest oncological beneﬁt, with a reduction in
overall mortality of 25.5% and a prostate cancer death reduction ofustin Health, 145 Studley Rd,
era).
ciﬁc Prostate Society, Published b15.8% following prostatectomy.3 Furthermore, this study reported
that in men aged  65 years, the number needed to treat to avert
one death was only four. These ﬁndings suggest that early prostate
cancer diagnosis and management is critical in this younger
population.
Transurethral resection of the prostate (TURP) targets the
transitional zone of the prostate. Prostate cancer isolated exclu-
sively in the transitional zone (TZ) is uncommon, accounting for
only 2e7% of all prostate cancers.4e6 Several recent studies have
reported that cancer arising from the TZ have a more favorable
prognosis than tumors that arise in the peripheral zone (PZ).4,7 As a
result, several groups argue that the TURP specimen may hold
limited diagnostic value.8 In the postprostate-speciﬁc antigen (PSA)
testing era, incidental prostate cancer (ICP) on TURP remains
common, occurring in 4.1e16.7% of TURP specimens.9,10 Despitey Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 4 (2016) 11e1412this prevalence, oncological outcomes have been poorly studied,
with small series suggesting favorable survival.11
Unfortunately, there is no consensus on pathological assessment
of TURP specimens. Standard handling of these specimens includes
embedding and analyzing only part of larger specimen. The College
of American Pathologists (CAP) recommend that specimens
weighing  12 g should be examined in entirety. For specimens
weighing > 12 g, the initial 12 g should be assessed with the
addition of 2 g of tissue for every 10 g of specimen.12e14 Intuitively,
embedding the entire TURP specimen for histological examination
will lead to a higher rate of identiﬁcation of prostate cancer.15
Despite this, literature suggests that partial assessment detects up
to 90e100% of incidental cancer on TURP specimens.16,17
Given the importance of diagnosis in men aged  65 years as
outlined, there is an argument for assessment of the entire spec-
imen in men of this age group. In the current study, we aimed to
determine the frequency of incidental cancer on TURP accurately in
men aged  65 years by completely assessing pathological speci-
mens. Outcomes produced by Bill-Axelson et al2 are not directly
comparable with the incidental PC and thus we further aimed to
establish the prostate cancer outcomes in these young patients
following diagnosis. This information is of interest in the climate of
laser prostatectomy, which is characterized by the absence of
pathological specimens for analysis.2. Materials and methods
2.1. Patients
Following Human Research and Ethic Committee (HREC)
approval, a multisurgeon, multicentre database was prospectively
collected and utilized for analysis. All consecutive TURP specimens
collected between January 2010 and December 2013were recruited
for the study. Pathological assessment was conducted by a single-
specialist uropathologist at a high-volume uropathology service.
The cohort was subdivided into two discrete groups based on age;
Group A representedmen aged 65 years and Group B represented
patients aged > 65 years.Table 1
Patient Demographics and Cancer Detection Rates in Each Group.
Group A (age  65 y) Group B (age> 65 y) P
n 224 699
Specimen weight (g) 14.0 (2e65) 11.0 (0.1e74) 0.33
Prostate cancer 30 (13.4%) 213 (28.7%) < 0.001
pT1a 17 92
pT1b 13 115
Acinar 27 197 0.50
Ductal 3 12
Urothelial 0 4
HGPIN 8 (3.6%) 24 (3.1%) 0.9
HGPIN, High-grade Prostatic Intraepithelial Neoplasia.
Table 2
Proportion of Patients in Each Group Categorized by Diagnosis and SpecimenWeight.
Diagnosis Group A (age  65 y) Group B (age> 65 y)
Specimen weight (g) < 12 > 12 < 12 > 12
Benign 91 (48.9) 95 (51.1) 290 (55.7) 231 (44.3)
Malignant 13 (43.3) 17 (56.6) 113 (53.1) 100 (46.9)
Data are presented as n (%).2.2. Specimen handling
All specimens were weighed. To assess incidental cancer in
Group A accurately, the complete resected specimen was
embedded and submitted for histopathological analysis. In Group B,
standard handling was performed on the specimen. For specimens
weighing  10 g, the entire specimenwas processed and examined
histologically. For specimens weighing > 10 g, the ﬁrst 10 g were
processed with an additional 2 g for every 10 g of tissue resected.
Thus, any specimen weight that exceeded 12 g marked the point at
which a limited specimen would be assessed as per the standard
handling protocol as outlined by CAP.14
The specimens were ﬁxed in 10% neutral buffered formalin with
overnight processing. A single hematoxylin and eosin-stained
section was cut from each block and examined histologically. All
foci were outlined on the glass slides and an estimate of tumor
volume as a visual estimate of the percentage of surface area of
tumor to the entire specimen determined. Gleason scoring was
based on the 2005 International Society of Urological Pathology
(ISUP) consensus guidelines. Small malignant foci were conﬁrmed
with immunoperoxidase stains using a cocktail of p504S (Dako,
Carpinteria, CA, USA. Clone 13H4 dilution 1:50), 34BE12 (Dako,
Carpinteria, CA, USA. Clone 34BE12 dilution 1:50) and p63 (Leica,
Buffalo Grove, IL, USA. Clone 7JUL dilution 1:25), using the Ventana
Ultra automated immunoperoxidase stainer, Roche, Switzerland).Reporting of incidental cancer on TURP aligned with the CAP
recommendations.14 pT1a disease was deﬁned as incidental tumor
in  5% of TURP specimens. pT1b disease was deﬁned as incidental
tumor in > 5% of TURP specimens.
2.3. Data collection and analysis
Limited preoperative and postoperative data were collected
from medical records. Such data included patient demographics.
Follow-up data were collected prospectively in a similar method,
variables collected included: subsequent transrectal ultrasonogra-
phy (TRUS) biopsy, prostatectomy, radiotherapy, androgen depri-
vation, or chemotherapy.
Data were collated on an Excel 2003 database (Microsoft Corp.,
Redmond, WA, USA). Statistical analysis was completed on SPSS
statistical package v20 (SPSS Inc, Chicago, IL, USA). Groups were
classed based on the aforementioned age criterion. Chi-square t test
was used to assess categorical data where possible. Two-sided
P< 0.05 was considered statistically signiﬁcant.
3. Results
A total of 923 patients were recruited into the study, 224 in
Group A and 699 in Group B. The patient demographics and cancer
detection rates are outlined in Table 1. On histopathological
assessment of the TURP specimen, prostate cancer was diagnosed
in 13.4% of the younger group and 28.7% in the older group. The
younger group had a higher proportion of low-volume disease
(pT1a). Of the diagnosed prostate cancers, the 92.2% were of acinar
adenocarcinoma subtype, with similar proportions between sub-
groups. Within the younger group, a signiﬁcantly higher rate of
low-grade prostate cancer was diagnosed (Gleason score  6).
Each group was further subdivided into categories based on
specimen weight. Within the younger group, 57% of the patients
diagnosed with cancer had a specimen weight > 12 g. In the
younger group, the median number of blocks embedded for anal-
ysis was seven (range, 1e27) and the median number of positive
blocks with cancer was one (range, 1e5). In the younger group, 15/
30 cancers diagnosed had cancer in only one block. These results
are summarized in Table 2.
Following TURP, of the men in Group A diagnosed with cancer,
6/30 underwent TRUS biopsy. The results are shown in Table 3.
Table 3
Transrectal Ultrasonography (TRUS) and Prostatectomy Findings in Men in GROUP A (Age  65 y).
PSA TURP Gleason TURP stage TRUS Gleason TRUSþ cores RP Gleason RP stage, tumor volume
Case 1 26.9 4 þ 5¼ 9 pT1b 5 þ 5¼ 10 12/12 cores NP NP
Case 2 5.5 3 þ 3¼ 6 pT1a 3 þ 3¼ 6 1/12 cores G3 þ 3¼ 7 pT2c, 0.2cc
Case 3 0.69 3 þ 3¼ 6 pT1a Benign NP NP NP
Case 4 2.7 3 þ 3¼ 6 pT1a 3 þ 4¼ 7 6/12 cores NP NP
Case 5 30.7 4 þ 3¼ 7 pT1a 4 þ 5¼ 9 11/12 cores G4 þ 5¼ 9 pT3a, 5.0cc
Case 6 4.5 3 þ 3¼ 6 pT1b NP NP G3 þ 3¼ 6 pT2c, 0.5cc
Case 7 3.7 3 þ 3¼ 6 pT1b NP NP G4 þ 5¼ 9 pT2a, NR
NP, not performed; PSA, prostate speciﬁc antigen; RP, radical prostatectomy; TURP, transurethral resection of prostate.
Table 4
Management Outcomes for Men in GROUP A Diagnosed with Cancer.
Group A: age  65 y
Active surveillance 19 (63.3)
Radical prostatectomy 4 (13.3)
RP only 3
RPþ RTx 1
RTx only 4 (13.3)
Curative 3
Palliative 1
RTxþADT 2 (6.6)
ADT only 1 (3.3)
Data are presented as n (%).
ADT, androgen deprivation therapy; RP, radical prostatectomy; RTx, radiotherapy.
Perera et al / Incidental cancer after TURP 13Further, 10/30 of these patients underwent some form of further
treatment for a new diagnosis of prostate cancer including: pros-
tatectomy, androgen deprivation or radiotherapy. One patient
received palliative radiotherapy (Table 4). Of the seven patients that
underwent either TRUS biopsy or prostatectomy, three experienced
upstaging to disease grade on subsequent pathological data (Cases
2, 5, and 7). The pathological ﬁndings for patients in Group A that
underwent TRUS biopsy or prostatectomy are summarized in
Table 3.
4. Discussion
The importance of diagnosis of prostate cancer in youngermales
is well established in contemporary urological practice. The current
study conﬁrms that ICP in younger men is common, having sig-
niﬁcant implication on further oncological management.
The histopathological signiﬁcance of TURP specimens has been
questioned following the introduction of PSA. Most prostate can-
cers arise from the PZ of the prostate, with recent studies sug-
gesting that isolated TZ tumors occur in only 2e7% of cancers.4e6 In
addition, TZ tumors tend to correspond with a more favorable
oncological outcome, including lower Gleason scores, rates of Ex-
tra-prostatic extension (EPE), and risk of biochemical recurrence.5Table 5
Previous Series Outlining Diagnosis of Incidental Prostate Cancers.
Author, yr Location Clinically benign Negat
Yoo et al23 Korea Yes Yes
Voigt et al18 Dresden, Germany NA, all cases NA, a
Bright et al19 Leicester, UK NA, all cases NA, a
Jones et al24 Cleveland, USA Yes Yes
Biers et al5 Winchester, UK NA, all cases NA, a
Trpkov et al20 Alberta, Canada NA, all cases NA, a
Antunes et al25 Sao Paulo, Brazil Yes Yes
Di Silvero et al8 Rome, Italy Yes Yes
Zigeuner et al10 Graz, Austria NA, all cases NA, a
Merrill and Wiggins9 Utah, USA NA, all cases NA, a
Mai et al22 Ontario, Canada NA, all cases NA, a
Data are presented as n (%).
NA, not applicable; nr, not reported; RP, radical prostatectomy; TRUS, transrectal ultrasoIntuitively, TURP tends to result in the resection of the TZ, while
the PZ is sampled the least with this treatment. Given this, many
suggest that concerns regarding missed ICP may not be clinically
signiﬁcant. In the current study, ICP on TURP specimens remains
common, occurring in up to 26% of patients. This ﬁgure remained
signiﬁcant on subgroup analysis in men aged  65 years at 13.4%.
These ﬁgures of ICP on all TURP specimens are higher when
compared with previous literature, with reported rates of
4.1e16.7%,5,10,18e22 summarized in Table 5. When patients with
suspicious rectal examination, high PSA, or previous positive biopsy
are excluded, ICP occurs less frequently at 1.8e5.5%.23e26
The relatively high rates of ICP may be the result of pathologist
opinion or methodology of specimen processing. Specimens in
Group A underwent extended assessment, including histological
assessment of the entire specimen, regardless of specimen weight.
In this group, 57% of cancers diagnosed had a specimen weight >
12 g. In laboratories that perform standard handling as suggested
by CAP, the potential for a missed diagnosis becomes apparent.
Further, of the cancers diagnosed in the younger group, 50% of cases
had cancer in only one block. These ﬁndings suggest embedding
and assessment of complete specimens should occur to maintain
diagnostic accuracy. The cost implications of such practice must be
considered and represents scope for further research.
Within the younger cohort (Group A), a signiﬁcant proportion
diagnosed with cancer on TURP underwent further oncological
management. Of these men 10/30 (33%) underwent some form of
treatment with a curative intent including prostatectomy, radio-
therapy, or androgen deprivation. Interestingly, staging on TURP
tends to predict the stage of subsequent specimens obtained from
transrectal biopsies and prostatectomy. However, anecdotally, this
is not entirely reliable, as seen in Case 6 in the TRUS specimens
(Table 3). Furthermore, several cases were signiﬁcantly upstaged on
subsequent pathological assessment (Cases 2, 5, and 7). Due to this,
we recommend that all patients diagnosed with cancer on TURP
should undergo further pathological testing to clarify the extent of
the local disease. In particular, patients being considered for active
surveillance following low-grade prostate cancer on TURP shouldive TRUS Mean age (y) Number TURP Number cancer
71 1,613 (included RP) 78 (4.8)
ll cases 69 1,000 111 (11.1)
ll cases 72 476 47 (9.9)
nr 501 26 (5.2)
ll cases 77 680 23 (4.1)
ll cases 747 126 (16.7)
68 168 3 (1.8)
69 3942 217 (5.5)
ll cases 72 2422 314 (13)
ll cases nr 6,426 675 (10.5)
ll cases nr 449 36 (8.0)
und biopsy of prostate; TURP, transurethral resection of prostate.
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peripheral zone.
The current study suggests that detection of ICP on TURPmay be
clinically signiﬁcant, even in a younger cohort. The introduction of
nonablative therapies, such as laser prostatectomy or urolift, pose
the difﬁcult issue of a lack of prostatic specimen for histopatho-
logical analysis, potentially leading to diagnostic compromise. This
situation poses the questiondshould we be performing transrectal
biopsies targeting the transitional zone prior to, or during, laser
prostatectomy to exclude prostate cancer? Alternatively, is moni-
toring the trend in PSA following the establishment of a new
baseline sufﬁcient?
Several limitations were identiﬁed within the current study.
Histopathological analysis was performed by a single uropatholo-
gist and may account for a high rate of prostate cancer through
overdiagnosis. To address this concern, all small foci were
conﬁrmed with PIN4 immunoperoxidase stains. The cohort exam-
ined in the study represents patients from the private sector within
Australian practice, potentially introducing selection bias. This
cohort may have also been exposed to a more aggressive treatment
protocol. While this study identiﬁes the importance of diagnosis of
ICP in younger males, a larger, more comprehensive study is
required to ascertain rates in the larger population and clinical
signiﬁcance. Crucial clinical details were not available for analysis
including PSA, digital rectal examination ﬁndings, and previous
medical history.
The current study shows that prostate cancer is not uncommon
in TURP specimens in men up to age 65 years. Many of these can-
cers are clinically signiﬁcant, requiring further oncological man-
agement. Despite thorough histopathological assessment, 50% of
cases had tumor in only one block. These ﬁndings suggest that all of
the TURP specimens in men up to 65 years should be submitted for
pathological examination. These ﬁndings are also of importance
given the increasing use of laser prostatectomy and the consequent
loss of tissue for pathological examination. This may lead to an
underidentiﬁcation of cancer in these men.
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